|[October 16, 2013]
Diaxonhit Enters into Exclusive Partnership Agreement with Japanese Tosoh Group for Marketing Immunoassay Instruments
PARIS --(Business Wire)--
Regulatory News :
Diaxonhit (Paris:ALEHT) strengthens its offering in the field of
immunoassays for clinical laboratories with the signing by InGen, its
commercialization affiliate, of a partnership agreement with the
Japanese group Tosoh Europe NV for the marketing of immunoassay
instruments in France and its overseas territories.
Diaxonhit is already active in the field of immunoassays, which
represented approximately 12% of its sales as at June 30, 2013. With
this agreement, the Group will be able to offer to clinical laboratories
two high-performance automated systems manufactured by Tosoh, the AIA360
and AIA900. These high-speed instruments with 36 and 90 tests/hour,
respectively, offer a choice of 44 different parameters with a
recognized operational reliability. The ability of these devices to
facilitate quality accreditation is also a major asset.
In France, with an increased concentration of private clinical
laboratories implicated by the ongoing medical biology reform, the
market is moving towards implementation of centralized diagnostic test
platforms in which the demand for high-performance equipment, in terms
of speed, parameters and quality is strong. Diaxonhit's new offer
directly addresses these requirements.
Working closely with Tosoh Bioscience France, Diaxonhit brings to this
partnership its expertise in immunoassays with hospital biologists, such
as those of the Paris and Marseille Hospitals or the private sector.
This agreement allows both companies to provide customized solutions to
better meet current trends in medical biology.
Among the techniques used for in vitro diagnostic testing,
immunoassays are based on the biological principles of the immune system
to detect and measure secific elements. They use antigen and antibody
characteristics, and in particular the ability of the latter to
specifically bind to certain molecules.
Immunoanalysis is quite widespread in clinical laboratories. In 2012,
immunochemistry accounted for 37% of the total in vitro
diagnostic reagents market in France(1). Utilized on
automatic analysis systems, these reagents are used to carry out tests
in multiple indications such as heart failure (blood level measurements
of BNP, Troponin), vitamin deficiency (blood level measurements of
vitamin D, B9, B12), pregnancy monitoring (blood level measurements of
beta HCG), and many other tests in the field of infectious diseases.
Automated instruments, on which immunoassays are performed, are
characterized by their speed (number of tests per hour), the number of
different tests that can be performed (number of parameters), and the
ability of the equipment to interact with the laboratory quality system.
(1) Source (News - Alert) : SIDIV (July 2013)
Diaxonhit (NYSE Alternext, FR0004054427, ALEHT) is a French fully
integrated leader in the in-vitro diagnostic field, involved from
research to commercialization of specialty diagnostic products.
With many partnerships and a strong presence in hospitals, Diaxonhit has
an extensive commercialization network. Through its affiliate, InGen, it
commercializes and services, mostly under exclusivity agreements,
in-vitro diagnostic kits and advanced equipment. It operates mainly in
the fields of transplantation, infectious diseases and autoimmunity,
product quality control and rapid tests, including Tetanus Quick Stick
®, a proprietary product. InGen is the leading supplier in France of HLA
tests manufactured by Thermo-Fisher/One Lambda, of which it is the
largest distributor worldwide.
The group also owns a diversified portfolio of products in development,
including both innovative molecular and non-molecular diagnostics,
covering three main specialty areas: immuno-infection, Alzheimer's
disease and cancer.
Diaxonhit headquarters are located in Paris and its affiliate in the
Paris region. The Group is listed on NYSE Alternext in Paris and is part
of the NYSE Alternext OSEO innovation index.
For more information, please visit: http://www.diaxonhit.com.
This press release contains elements that are not historical facts
including, without limitation, certain statements about future
expectations and other forward-looking statements. Such statements are
based on management's current views and assumptions and involve known
and unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those anticipated.
In addition, Diaxonhit, its shareholders, and its affiliates,
directors, officers, advisors and employees have not verified the
accuracy of, and make no representations or warranties in relation to,
statistical data or predictions contained in this press release that
were taken or derived from third party sources or industry publications,
and such statistical data and predictions are used in this press release
for information purposes only.
Finally, this press release may be drafted in the French and English
languages. In an event of differences between the texts, the French
language version shall prevail.
[ Back To Technology News's Homepage ]